Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients

被引:73
作者
Francque, Sven M. A. [1 ]
Verrijken, An [2 ]
Mertens, Ilse [2 ]
Hubens, Guy [3 ]
Van Marck, Eric [4 ]
Pelckmans, Paul [1 ]
Michielsen, Peter [1 ]
Van Gaal, Luc [2 ]
机构
[1] Univ Antwerp Hosp, Dept Gastroenterol & Hepatol, Antwerp, Belgium
[2] Univ Antwerp Hosp, Dept Diabet Endocrinol & Metab, Antwerp, Belgium
[3] Univ Antwerp Hosp, Dept Abdominal Surg, Antwerp, Belgium
[4] Univ Antwerp Hosp, Dept Pathol, Antwerp, Belgium
关键词
Risk Factor; Liver Disease; Complication; Genetic Test; Liver Stiffness; SIGNIFICANT FIBROSIS; METABOLIC SYNDROME; HEPATIC STEATOSIS; SCORING SYSTEM; STEATOHEPATITIS; VALIDATION; INDEX; NAFLD; PREDICTION;
D O I
10.1016/j.cgh.2012.06.019
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Reliable noninvasive tools are needed for staging nonalcoholic fatty liver disease (NAFLD). Published scoring systems have not been validated in prospective assessments of unselected patients. We aimed to identify factors that predicted development of nonalcoholic steatohepatitis (NASH) in a large group of overweight or obese patients and compared these with established factors. METHODS: We performed a prospective analysis of factors associated with the development and severity of NAFLD in patients at a single obesity center. We evaluated liver involvement in 542 patients by a large set of routine and non-routine parameters, including ultrasound and genetic testing. Those suspected of having NAFLD underwent liver biopsy (57.7%). Patients were divided into design cohort (n = 200) and validation cohort (n = 113) to identify factors associated with the presence and severity of NAFLD and NASH. RESULTS: Factors independently associated with development of NASH included increased levels of alanine aminotransferase (ALT), fasting levels of C-peptide, and ultrasound steatosis scores (USSs), with area under the receiver operating curve (AUROC) values of 0.854 in the design cohort and 0.823 in the validation cohort. NASH activity scores also correlated with level of ALT, USS, and fasting level of C-peptide (R-2 = 0.491). Independent predictors of advanced fibrosis included waist circumference and level of aspartate aminotransferase (AUROC values of 0.839 and 0.846 for design and validation cohorts, respectively; negative predictive values of 98% and 97%, respectively, for a cutoff of -2.14). Previously published scoring systems had significantly lower AUROC values. Levels of CK18 and PNPLA3 polymorphisms correlated with development of NASH but did not add value. CONCLUSIONS: Parameters routinely analyzed in assessing obese patients can be used to determine the presence of NASH and advanced fibrosis. Non-routine tests do not increase diagnostic accuracy. Previously published scores are significantly less accurate.
引用
收藏
页码:1162 / 1168
页数:7
相关论文
共 26 条
[1]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[2]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[3]   The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population [J].
Bedogni, Giorgio ;
Bellentani, Stefano ;
Miglioli, Lucia ;
Masutti, Flora ;
Passalacqua, Marilena ;
Castiglione, Anna ;
Tiribelli, Claudio .
BMC GASTROENTEROLOGY, 2006, 6 (1)
[4]   Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings [J].
Brunt, Elizabeth M. ;
Kleiner, David E. ;
Wilson, Laura A. ;
Belt, Patricia ;
Neuschwander-Tetri, Brent A. .
HEPATOLOGY, 2011, 53 (03) :810-820
[5]  
Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x
[6]   Insulin resistance: A metabolic pathway to chronic liver disease [J].
Bugianesi, E ;
McCullough, AJ ;
Marchesini, G .
HEPATOLOGY, 2005, 42 (05) :987-1000
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model [J].
Forns, X ;
Ampurdanès, S ;
Llovet, JM ;
Aponte, J ;
Quintó, L ;
Martínez-Bauer, E ;
Bruguera, M ;
Sánchez-Tapias, JM ;
Rodés, J .
HEPATOLOGY, 2002, 36 (04) :986-992
[9]   Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis [J].
Francque, Sven ;
Verrijken, An ;
Mertens, Ilse ;
Hubens, Guy ;
Van Marck, Eric ;
Pelckmans, Paul ;
Van Gaal, Luc ;
Michielsen, Peter .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (12) :1449-1457
[10]   Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease [J].
Harrison, S. A. ;
Oliver, D. ;
Arnold, H. L. ;
Gogia, S. ;
Neuschwander-Tetri, B. A. .
GUT, 2008, 57 (10) :1441-1447